Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 9,622 calls trading, 2x expected, and implied vol increasing almost 27 ...

Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

Shares of Atara Biotherapeutics (ATRA) have gained 11.4% over the past four weeks to close the last trading session at $8.72, but there could still be a solid upside left in the stock if short-term ...

Arcutis Biotherapeutics, Inc. (ARQT) shares rallied 15.9% in the last trading session to close at $13.21. This move can be attributable to notable volume with a higher number of shares being traded ...

A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. Other equities ...

Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE ...